Live Breaking News & Updates on Angelini Pharma Daniela Poggio Head

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults
January 29, 2021 12:20 ET
| Source:
Arvelle Therapeutics
Arvelle Therapeutics
Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate
When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom
ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of cenobamate for the ....

United Kingdom , Mark Altmeyer , Juan Vergez , Engelj Ann Indian , Nick James , Angelini Pharma , Pierluigi Antonelli , Chloe Nichols , Trio Health Nina Bass , Mental Health , European Union , Sk Biopharmaceuticals Hyongki Park Head Of Communications , Angelini Pharma Daniela Poggio Head Of Communications , Committee For Medicinal Products Human Use , Sk Biopharmaceuticals Co Ltd , German Federal Institute For Drugs , Global Campaign Against Epilepsy , Drug Administration , World Health Organization , European Commission , Angelini Group , Corporate Communications , Epilepsy Alliance Europe , European Medicines Agency , Healthcare Products Regulatory Agency , Arvelle Therapeutics ,